The E3 ubiquitin ligase FBXL6 controls the quality of newly synthesized mitochondrial ribosomal proteins.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
27 06 2023
Historique:
received: 21 12 2022
revised: 03 04 2023
accepted: 15 05 2023
medline: 4 10 2023
pubmed: 2 6 2023
entrez: 2 6 2023
Statut: ppublish

Résumé

In mammals, about 99% of mitochondrial proteins are synthesized in the cytosol as precursors that are subsequently imported into the organelle. The mitochondrial health and functions rely on an accurate quality control of these imported proteins. Here, we show that the E3 ubiquitin ligase F box/leucine-rich-repeat protein 6 (FBXL6) regulates the quality of cytosolically translated mitochondrial proteins. Indeed, we found that FBXL6 substrates are newly synthesized mitochondrial ribosomal proteins. This E3 binds to chaperones involved in the folding and trafficking of newly synthesized peptide and to ribosomal-associated quality control proteins. Deletion of these interacting partners is sufficient to hamper interactions between FBXL6 and its substrate. Furthermore, we show that cells lacking FBXL6 fail to degrade specifically mistranslated mitochondrial ribosomal proteins. Finally, showing the role of FBXL6-dependent mechanism, FBXL6-knockout (KO) cells display mitochondrial ribosomal protein aggregations, altered mitochondrial metabolism, and inhibited cell cycle in oxidative conditions.

Identifiants

pubmed: 37267103
pii: S2211-1247(23)00590-9
doi: 10.1016/j.celrep.2023.112579
pii:
doi:

Substances chimiques

Mitochondrial Proteins 0
Ribosomal Proteins 0
Ubiquitin-Protein Ligases EC 2.3.2.27
FBXL6 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112579

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Julie Lavie (J)

Laboratoire Maladies Rares: Génétique et Métabolisme, INSERM U1211, 33076 Bordeaux, France; Université de Bordeaux, 33000 Bordeaux, France.

Claude Lalou (C)

Laboratoire Maladies Rares: Génétique et Métabolisme, INSERM U1211, 33076 Bordeaux, France; Université de Bordeaux, 33000 Bordeaux, France.

Walid Mahfouf (W)

Université de Bordeaux, 33000 Bordeaux, France; Université de Bordeaux, INSERM, UMR1312, Bordeaux Institute of Oncology, Bordeaux, France.

Jean-William Dupuy (JW)

Université de Bordeaux, 33000 Bordeaux, France; Université de Bordeaux, Plateforme Protéome, 33000 Bordeaux, France.

Aurélie Lacaule (A)

Laboratoire Maladies Rares: Génétique et Métabolisme, INSERM U1211, 33076 Bordeaux, France; Université de Bordeaux, 33000 Bordeaux, France.

Agata Ars Cywinska (AA)

Laboratoire Maladies Rares: Génétique et Métabolisme, INSERM U1211, 33076 Bordeaux, France; Université de Bordeaux, 33000 Bordeaux, France.

Didier Lacombe (D)

Laboratoire Maladies Rares: Génétique et Métabolisme, INSERM U1211, 33076 Bordeaux, France; Université de Bordeaux, 33000 Bordeaux, France; CHU Bordeaux, Service de Génétique Médicale, 33076 Bordeaux, France.

Anne-Marie Duchêne (AM)

Université de Strasbourg, CNRS, Institut de Biologie Moléculaire des Plantes, UPR2357, 67000 Strasbourg, France.

Anne-Aurélie Raymond (AA)

Université de Bordeaux, 33000 Bordeaux, France; Université de Bordeaux, INSERM, UMR1312, Bordeaux Institute of Oncology, Bordeaux, France; Plateforme Oncoprot, TBM-Core US 005, 33000 Bordeaux, France.

Hamid Reza Rezvani (HR)

Université de Bordeaux, 33000 Bordeaux, France; Université de Bordeaux, INSERM, UMR1312, Bordeaux Institute of Oncology, Bordeaux, France.

Richard Patryk Ngondo (RP)

Université de Strasbourg, CNRS, Institut de Biologie Moléculaire des Plantes, UPR2357, 67000 Strasbourg, France; Université de Strasbourg, CNRS, Architecture et Réactivité de l'ARN, UPR9002, 67000 Strasbourg, France.

Giovanni Bénard (G)

Laboratoire Maladies Rares: Génétique et Métabolisme, INSERM U1211, 33076 Bordeaux, France; Université de Bordeaux, 33000 Bordeaux, France. Electronic address: giovanni.benard@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH